Literature DB >> 20156131

Identification of ovarian cancer symptoms in health insurance claims data.

Sean M Devlin1, Paula H Diehr, M Robyn Andersen, Barbara A Goff, Patrick T Tyree, William E Lafferty.   

Abstract

BACKGROUND: Women with ovarian cancer have reported abdominal/pelvic pain, bloating, difficulty eating or feeling full quickly, and urinary frequency/urgency prior to diagnosis. We explored these findings in a general population using a dataset of insured women aged 40-64 and investigated the potential effectiveness of a routine review of claims data as a prescreen to identify women at high risk for ovarian cancer.
METHODS: Data from a large Washington State health insurer were merged with the Seattle-Puget Sound Surveillance, Epidemiology and End Results (SEER) cancer registry for 2000-2004. We estimated the prevalence of symptoms in the 36 months prior to diagnosis for early and late-stage ovarian cancer cases and for two comparison groups. The potential performance of a passive screener that would flag women with two or more visits for any of the symptoms in the previous 2-month period was examined.
RESULTS: Of the 223,903 insured women, 161 had incident cases of ovarian cancer. Both early and late-stage patients had a higher prevalence of abdominal/pelvic pain and bloating than the comparison groups, primarily in the 3 months before diagnosis. The passive screener had a sensitivity of 0.31 and specificity of 0.83 and usually identified women right before diagnosis. Assuming an average cost of $500 per false positive, the screener would be considered cost-effective if the true positives had an average increase of 8.5 years of life expectancy.
CONCLUSIONS: These results support previous findings that ovarian cancer symptoms were reported in health insurance claims and were more prevalent before diagnosis, but the symptoms may occur too close to the diagnosis date to provide useful diagnostic information. The passive screening approach should be reevaluated in the future using electronic medical records; if found to be effective, the method may be potentially useful for other incident diseases.

Entities:  

Mesh:

Year:  2010        PMID: 20156131      PMCID: PMC2867625          DOI: 10.1089/jwh.2009.1550

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  15 in total

Review 1.  The surveillance, epidemiology, and end results program: a national resource.

Authors:  B F Hankey; L A Ries; B K Edwards
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-12       Impact factor: 4.254

2.  Ovarian cancer: can we make the clinical diagnosis earlier?

Authors:  Lloyd H Smith; Cyllene R Morris; Shagufta Yasmeen; Arti Parikh-Patel; Rosemary D Cress; Patrick S Romano
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

3.  Temporal patterns of conditions and symptoms potentially associated with ovarian cancer.

Authors:  Michelle L Wynn; Stella Chang; Lucy A Peipins
Journal:  J Womens Health (Larchmt)       Date:  2007-09       Impact factor: 2.681

Review 4.  Clinical practice. Screening for ovarian cancer.

Authors:  Daniel L Clarke-Pearson
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

5.  Insurance coverage and subsequent utilization of complementary and alternative medicine providers.

Authors:  William E Lafferty; Patrick T Tyree; Allen S Bellas; Carolyn A Watts; Bonnie K Lind; Karen J Sherman; Daniel C Cherkin; David E Grembowski
Journal:  Am J Manag Care       Date:  2006-07       Impact factor: 2.229

6.  Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.

Authors:  M F Vine; R B Ness; B Calingaert; J M Schildkraut; A Berchuck
Journal:  Gynecol Oncol       Date:  2001-12       Impact factor: 5.482

7.  Development of an ovarian cancer symptom index: possibilities for earlier detection.

Authors:  Barbara A Goff; Lynn S Mandel; Charles W Drescher; Nicole Urban; Shirley Gough; Kristi M Schurman; Joshua Patras; Barry S Mahony; M Robyn Andersen
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

8.  Complementary and alternative medicine provider use and expenditures by cancer treatment phase.

Authors:  William E Lafferty; Patrick T Tyree; Sean M Devlin; M Robyn Andersen; Paula K Diehr
Journal:  Am J Manag Care       Date:  2008-05       Impact factor: 2.229

9.  Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.

Authors:  Barbara A Goff; Lynn S Mandel; Cindy H Melancon; Howard G Muntz
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute.

Authors:  C Zippin; D Lum; B F Hankey
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

View more
  5 in total

1.  Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability.

Authors:  Barbara A Goff; Kimberly A Lowe; Jeannette C Kane; Marissa D Robertson; Marcia A Gaul; M Robyn Andersen
Journal:  Gynecol Oncol       Date:  2011-11-06       Impact factor: 5.482

2.  Effects of Demographics and OTC Analgesics on Ovarian Cancer Symptoms.

Authors:  Kimberly A Lowe; M Robyn Andersen; Jeannette C Kane; Marissa D Robertson; Barbara A Goff
Journal:  J Nurse Pract       Date:  2013-01       Impact factor: 0.767

3.  Physicians' beliefs about effectiveness of cancer screening tests: a national survey of family physicians, general internists, and obstetrician-gynecologists.

Authors:  Jacqueline W Miller; Laura-Mae Baldwin; Barbara Matthews; Katrina F Trivers; C Holly Andrilla; Denise Lishner; Barbara A Goff
Journal:  Prev Med       Date:  2014-07-17       Impact factor: 4.018

4.  Gynaecologic cancer symptom awareness, concern and care seeking among US women: a multi-site qualitative study.

Authors:  Crystale Purvis Cooper; Lindsey Polonec; Sherri L Stewart; Cynthia A Gelb
Journal:  Fam Pract       Date:  2012-09-03       Impact factor: 2.267

5.  Symptoms in Blastomycosis, Coccidioidomycosis, and Histoplasmosis Versus Other Respiratory Illnesses in Commercially Insured Adult Outpatients-United States, 2016-2017.

Authors:  Kaitlin Benedict; Miwako Kobayashi; Shikha Garg; Tom Chiller; Brendan R Jackson
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.